• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)

PRODUCT FILTERS

REGION

350
64
46
44
20

COUNTRY

43
11
5
5
4

PRICE

209
454
669
1,257

PUBLISHED

44
156
401
1,257

PRODUCT TYPE

1,225
17
11
4

Central Nervous System

In 2012 major changes might revolutionize the treatment of multiple sclerosis, as Gilenya, the first novel drug in five years, will be joined by three new products: BG-12, Aubagio, and Lemtrada. Recent exciting developments in drug discovery might also enhance the hopes of those fighting against Alzheimer.

Great commercial and scientific opportunities are to be found in similar battles against a range of diseases and neurodegenerative disorders, e.g. Parkinson’s disease, schizophrenia, migraine, insomnia, epilepsy, etc.

A wide selection of industry reports, scientific journals and academic textbooks in this section allow readers to explore every conceivable facet of this industry, such as market trends, industry forecasts, new drugs in development, the latest research & development, patent applications, and licensing strategies.

Key players featured in our publications include Biogen Idec, Sanofi, Genzyme, and many more. Show Less
Read more

PRODUCT TITLE

Cymbalta (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Cymbalta (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded...

May 2014
FROM

Fetzima (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Fetzima (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded...

May 2014
FROM

Cariprazine (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Cariprazine (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a...

May 2014
FROM

Amitifadine (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Amitifadine (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a...

May 2014
FROM

Effexor (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Effexor (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded...

May 2014
FROM

ALKS-5461 (Major Depressive Disorder) - Forecast and Market Analysis to 2023

ALKS-5461 (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded...

May 2014
FROM

PharmaPoint: Major Depressive Disorder - 5EU Drug Forecast and Market Analysis to 2023

PharmaPoint: Major Depressive Disorder - 5EU Drug Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market...

May 2014
FROM

Pristiq (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Pristiq (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded...

May 2014
FROM

Savella (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Savella (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded...

May 2014
FROM

PharmaPoint: Major Depressive Disorder - Current and Future Players

PharmaPoint: Major Depressive Disorder - Current and Future Players Summary GlobalData has released its pharma report, “PharmaPoint: Major Depressive Disorder - Current and Future Players”. The report...

May 2014
FROM

Lexapro (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Lexapro (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded...

May 2014
FROM

Brintellix (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Brintellix (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a...

May 2014
FROM

Tedatioxetine (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Tedatioxetine (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is...

May 2014
FROM

ETS6103 (Major Depressive Disorder) - Forecast and Market Analysis to 2023

ETS6103 (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded...

May 2014
FROM

PharmaPoint: Major Depressive Disorder - Australia Drug Forecast and Market Analysis to 2023

PharmaPoint: Major Depressive Disorder - Australia Drug Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD...

May 2014
FROM

Abilify (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Abilify (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded...

May 2014
FROM

Seroquel XR (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Seroquel XR (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a...

May 2014
FROM

GLYX-13 (Major Depressive Disorder) - Forecast and Market Analysis to 2023

GLYX-13 (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded...

May 2014
FROM

PharmaPoint: Major Depressive Disorder - Japan Drug Forecast and Market Analysis to 2023

PharmaPoint: Major Depressive Disorder - Japan Drug Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market...

May 2014
FROM

Brexpiprazole (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Brexpiprazole (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is...

May 2014
FROM
Loading Indicator

Our Clients

Our clients' logos